PMID- 21173791
OWN - NLM
STAT- MEDLINE
DCOM- 20110606
LR  - 20151119
IS  - 1476-5608 (Electronic)
IS  - 1365-7852 (Linking)
VI  - 14
IP  - 1
DP  - 2011 Mar
TI  - Prognostic value of connexin43 expression in patients with clinically localized 
      prostate cancer.
PG  - 90-5
LID - 10.1038/pcan.2010.51 [doi]
AB  - Connexins (Cxs) are a family of transmembrane proteins that build cell-to-cell 
      channels in gap junctions. Gap junctions composed of Cxs have an essential role 
      in intercellular communication, adhesion and cell differentiation. Several 
      studies investigated the role of connexin43 (Cx43) in different carcinomas; 
      however, none investigated its prognostic role in prostate cancer. Cx43 
      expression and relationship with established prognostic features were assessed in 
      a cohort of 102 patients treated with radical prostatectomy for clinically 
      localized prostate adenocarcinoma. Cx43 expression in prostate cancer was 
      significantly associated with established features indicative of worse prognosis, 
      such as follow-up time (P < 0.001) and preoperative PSA (P < 0.007). Patients 
      with lower Cx43 expressions in tumours have shorter follow-up time, which 
      indicated shorter disease-free survival and higher preoperative PSA values. 
      Furthermore, tumours with positive surgical margins (P < 0.001) showed 
      significantly lower Cx43 expression compared with tumours without this feature. 
      In univariate (P < 0.001) and multivariate (P = 0.014) analyses, decreased Cx43 
      expression was found to be a significant predictor of biochemical recurrence 
      free-survival. Study results show the association of decreased Cx43 expression 
      with prostate cancer progression. Moreover, Cx43 could serve as an additional 
      prognostic marker and used together with traditional prognostic markers might 
      help in further stratifying the risk of disease progression in patients with 
      prostate cancer.
FAU - Benko, G
AU  - Benko G
AD  - Department of Urology, Varazdin General Hospital, Varazdin, Croatia.
FAU - Spajic, B
AU  - Spajic B
FAU - Demirovic, A
AU  - Demirovic A
FAU - Stimac, G
AU  - Stimac G
FAU - Kru Sbreve Lin, B
AU  - Kru Sbreve Lin B
FAU - Tomas, D
AU  - Tomas D
LA  - eng
PT  - Journal Article
DEP - 20101221
PL  - England
TA  - Prostate Cancer Prostatic Dis
JT  - Prostate cancer and prostatic diseases
JID - 9815755
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Connexin 43)
RN  - EC 3.4.21.77 (Prostate-Specific Antigen)
SB  - IM
MH  - Adenocarcinoma/*metabolism/pathology/surgery
MH  - Aged
MH  - Biomarkers, Tumor/*metabolism
MH  - Connexin 43/*metabolism
MH  - Disease Progression
MH  - Disease-Free Survival
MH  - Follow-Up Studies
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Prognosis
MH  - Prostate-Specific Antigen/blood
MH  - Prostatectomy
MH  - Prostatic Neoplasms/*metabolism/pathology/surgery
MH  - Time Factors
EDAT- 2010/12/22 06:00
MHDA- 2011/06/07 06:00
CRDT- 2010/12/22 06:00
PHST- 2010/12/22 06:00 [entrez]
PHST- 2010/12/22 06:00 [pubmed]
PHST- 2011/06/07 06:00 [medline]
AID - pcan201051 [pii]
AID - 10.1038/pcan.2010.51 [doi]
PST - ppublish
SO  - Prostate Cancer Prostatic Dis. 2011 Mar;14(1):90-5. doi: 10.1038/pcan.2010.51. 
      Epub 2010 Dec 21.